Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder

The study aimed to conduct a meta-analysis of studies comparing pharmacogenetically guided dosing of antidepressants with empiric standard of care. Publications referring to genotype-guided antidepressant therapy were identified via PubMed, Google Scholar, Scopus, Web of Science, Embase, and Cochran...

Full description

Saved in:
Bibliographic Details
Published in:The pharmacogenomics journal 2023-05, Vol.23 (2-3), p.45-49
Main Authors: Skryabin, Valentin, Rozochkin, Ilya, Zastrozhin, Mikhail, Lauschke, Volker, Franck, Johan, Bryun, Evgeny, Sychev, Dmitry
Format: Article
Language:English
Subjects:
38/77
45/77
631/208/212/1728
631/208/212/2166
Antidepressants
Antidepressive Agents - adverse effects
Biomedical and Life Sciences
Biomedicine
Decision Support Systems, Clinical
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - genetics
Dosage
Gene Expression
Genotypes
Genotyping
Human Genetics
Humans
Medicin och hälsovetenskap
Meta-analysis
Oncology
Patients
Pharmacogenetics
Pharmacotherapy
Psychopharmacology
Remission
Statistical analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aimed to conduct a meta-analysis of studies comparing pharmacogenetically guided dosing of antidepressants with empiric standard of care. Publications referring to genotype-guided antidepressant therapy were identified via PubMed, Google Scholar, Scopus, Web of Science, Embase, and Cochrane databases from the inception of the databases to 2021. In addition, bibliographies of all articles were manually searched for additional references not identified in primary searches. Studies comparing clinical outcomes between two groups of patients who received antidepressant treatment were included in meta-analysis. Analysis of the data revealed statistically significant differences between the experimental group receiving pharmacogenetically guided dosing and the empirically treated controls. Specifically, genotype-guided treatment significantly improved response and remission of patients after both eight and twelve weeks of therapy, whereas no effect on the development of adverse drug reactions was observed. This meta-analysis indicates that the use of preemptive genotyping to guide dosing of antidepressants might increase treatment efficacy.
ISSN:1470-269X
1473-1150
1473-1150
DOI:10.1038/s41397-022-00295-3